Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.
Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T. Aringer M, et al. Among authors: fleck m. Lupus. 2012 Apr;21(4):386-401. doi: 10.1177/0961203311426569. Epub 2011 Nov 9. Lupus. 2012. PMID: 22072024 Review.
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony HP, Unger L, Wassenberg S, Dörner T, Schulze-Koops H; German Registry of Autoimmune Diseases (GRAID) Investigators. Witt M, et al. Among authors: fleck m. Lupus. 2013 Oct;22(11):1142-9. doi: 10.1177/0961203313503912. Lupus. 2013. PMID: 24057058
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; GRAID investigators. Tony HP, et al. Among authors: fleck m. Arthritis Res Ther. 2011 May 13;13(3):R75. doi: 10.1186/ar3337. Arthritis Res Ther. 2011. PMID: 21569519 Free PMC article.
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP. Roll P, et al. Among authors: fleck m. J Rheumatol. 2012 Nov;39(11):2153-6. doi: 10.3899/jrheum.120482. Epub 2012 Sep 15. J Rheumatol. 2012. PMID: 22984269
[Macrophage activation syndrome].
Lehmann P, Huber E, Dörner T, Fleck M. Lehmann P, et al. Among authors: fleck m. Z Rheumatol. 2012 Oct;71(8):701-6. doi: 10.1007/s00393-012-0987-7. Z Rheumatol. 2012. PMID: 22836385 German.
[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].
Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüßlein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche A, Braun J. Kiltz U, et al. Among authors: fleck m. Z Rheumatol. 2016 Aug;75 Suppl 2:11-60. doi: 10.1007/s00393-016-0147-6. Z Rheumatol. 2016. PMID: 27481119 Review. German. No abstract available.
[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].
Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J. Kiltz U, et al. Among authors: fleck m. Z Rheumatol. 2017 Mar;76(2):118-124. doi: 10.1007/s00393-016-0249-1. Z Rheumatol. 2017. PMID: 28078432 Review. German.
Risk of infections in rheumatoid arthritis patients treated with tocilizumab.
Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, Tony HP, Fleck M, Manger B, Schett G, Zwerina J. Lang VR, et al. Among authors: fleck m. Rheumatology (Oxford). 2012 May;51(5):852-7. doi: 10.1093/rheumatology/ker223. Epub 2011 Aug 24. Rheumatology (Oxford). 2012. PMID: 21865281
[Evidence-based recommendations for the management of undifferentiated peripheral inflammatory arthritis (UPIA). The German perspective on the international 3e initiative].
Tarner IH, Albrecht K, Fleck M, Gromnica-Ihle E, Keyßer G, Köhler L, Kötter I, Krüger K, Kuipers J, Nüßlein H, Rubbert-Roth A, Wollenhaupt J, Schneider M, Manger B, Müller-Ladner U; internationalen 3e-Initiative. Tarner IH, et al. Among authors: fleck m. Z Rheumatol. 2014 May;73(4):363-73. doi: 10.1007/s00393-013-1249-z. Z Rheumatol. 2014. PMID: 24590079 German.
510 results